267 references, every PMID retrieved by direct query against the NCBI PubMed E-utilities API while this model was being built. Nothing here is recalled from memory. Sections follow the structure of the mechanistic map (pkd_qsp_model.dot) and the mrgsolve model (pkd_mrgsolve_model.R).

The model has four fitted parameters and roughly two hundred that are either taken from literature or back-calculated from the normal erythrocyte operating point. The list below is not "key papers"; it is the set of papers a specific number in the model came from, with the number named. If one of these is wrong, a stated result moves.

The single most load-bearing parameter is NOT in this table, and that is worth saying plainly: the 3-PG inhibition constant of the 2,3-BPG phosphatase (KIPG3 = 30 µM). It is what makes 2,3-BPG rise 2-fold rather than 9% when pyruvate kinase activity falls, and the entire oxygen-transport argument scales with the size of that excursion. It is the least well pinned number in the model. The break-even table in §3.2 of pkd_reference_output.txt exists so the conclusion can be re-scored against a different 2,3-BPG estimate without rebuilding anything.

31 references

• Tanaka KR. Pyruvate kinase deficiency. Semin Hematol 1971. PMID 4942588
• Waller HD. [Enzyme deficiencies in glycolysis and nucleotide metabolism of red blood cells in nonspherocytic hemolytic anemia (author's transl)]. Klin Wochenschr 1976. PMID 184346
• Zanella A. Hereditary pyruvate kinase deficiency: role of the abnormal enzyme in red cell pathophysiology. Br J Haematol 1978. PMID 728372
• Beutler E. Mutations in pyruvate kinase. Hum Mutat 1996. PMID 8664896
• Orosz F. Triosephosphate isomerase deficiency: predictions and facts. J Theor Biol 1996. PMID 8944178
• Orosz F. Triosephosphate isomerase deficiency: facts and doubts. IUBMB Life 2006. PMID 17424909
• Zanella A. Pyruvate kinase deficiency. Haematologica 2007. PMID 17550841
• Vijayan VK. Parasitic lung infections. Curr Opin Pulm Med 2009. PMID 19276810
• Bakhramov SM. [Erythrocytic enzymopathy in Uzbekistan]. Lik Sprava 2011. PMID 22768742
• Jamwal M. Next-generation sequencing unravels homozygous mutation in glucose-6-phosphate isomerase, GPIc.1040G>A (p.Arg347His) causing hemolysis in an Indi. Clin Chim Acta 2017. PMID 28223188
• Srivastava D. Structural Investigation of a Dimeric Variant of Pyruvate Kinase Muscle Isoform 2. Biochemistry 2017. PMID 29182273
• Grace RF. Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study. Blood 2018. PMID 29549173
• Grace RF. How we manage patients with pyruvate kinase deficiency. Br J Haematol 2019. PMID 30681718
• Segal J. Low catalytic activity is insufficient to induce disease pathology in triosephosphate isomerase deficiency. J Inherit Metab Dis 2019. PMID 31111503
• Srivastava D. Mechanistic and Structural Insights into Cysteine-Mediated Inhibition of Pyruvate Kinase Muscle Isoform 2. Biochemistry 2019. PMID 31386812
• Agarwal AM. Laboratory approach to investigation of anemia with a focus on pyruvate kinase deficiency. Int J Lab Hematol 2020. PMID 32543069
• Grace RF. Management of pyruvate kinase deficiency in children and adults. Blood 2020. PMID 32702739
• Nandi S. Structural basis for allosteric regulation of pyruvate kinase M2 by phosphorylation and acetylation. J Biol Chem 2020. PMID 33453989
• Secrest MH. Prevalence of pyruvate kinase deficiency: A systematic literature review. Eur J Haematol 2020. PMID 32279356
• Chhipa AS. Targeting pyruvate kinase muscle isoform 2 (PKM2) in cancer: What do we know so far?. Life Sci 2021. PMID 34102192
• Dongerdiye R. Novel pathogenic variant c.2714C>A (p. Thr905Lys) in the HK1 gene causing severe haemolytic anaemia with developmental delay in an Indian family. J Clin Pathol 2021. PMID 33361148
• Falak S. Molecular cloning, expression in Escherichia coli and structural-functional analysis of a pyruvate kinase from Pyrobaculum calidifontis. Int J Biol Macromol 2022. PMID 35472364
• Fattizzo B. Pyruvate Kinase Deficiency: Current Challenges and Future Prospects. J Blood Med 2022. PMID 36072510
• Hou DY. OGA activated glycopeptide-based nano-activator to activate PKM2 tetramerization for switching catabolic pathways and sensitizing chemotherapy re. Biomaterials 2022. PMID 35462306
• Johnson S. Diagnosis, monitoring, and management of pyruvate kinase deficiency in children. Pediatr Blood Cancer 2022. PMID 35452178
• VanDemark AP. Itavastatin and resveratrol increase triosephosphate isomerase protein in a newly identified variant of TPI deficiency. Dis Model Mech 2022. PMID 35315486
• Grace RF. The Pyruvate Kinase Deficiency Global Longitudinal (Peak) Registry: rationale and study design. BMJ Open 2023. PMID 36958777
• Al-Samkari H. Diagnosis and management of pyruvate kinase deficiency: international expert guidelines. Lancet Haematol 2024. PMID 38330977
• Holme S. Glucose phosphate isomerase deficiency demasked by whole-genome sequencing: a case report. J Med Case Rep 2024. PMID 38539245
• Ahmed SH. Efficacy and safety of pyruvate kinase activator in treating hemolytic anemias: a systematic review. Expert Rev Hematol 2025. PMID 40526104
• Williams A. TPI deficiency: A case report and review of the literature. Mol Genet Metab 2025. PMID 40897044

8 references

• Mueggler PA. Postnatal regulation of canine oxygen delivery: control of erythrocyte 2,3-DPG levels. Am J Physiol 1982. PMID 6278964
• Mulquiney PJ. Model of 2,3-bisphosphoglycerate metabolism in the human erythrocyte based on detailed enzyme kinetic equations: in vivo kinetic characterization. Biochem J 1999. PMID 10477268
• Kor DJ. Red blood cell storage lesion. Bosn J Basic Med Sci 2009. PMID 19912115
• Peng Z. Erythrocyte Adenosine A2B Receptor-Mediated AMPK Activation: A Missing Component Counteracting CKD by Promoting Oxygen Delivery. J Am Soc Nephrol 2019. PMID 31278195
• D'Alessandro A. Erythrocyte adaptive metabolic reprogramming under physiological and pathological hypoxia. Curr Opin Hematol 2020. PMID 32141895
• Xie T. Erythrocyte Metabolic Reprogramming by Sphingosine 1-Phosphate in Chronic Kidney Disease and Therapies. Circ Res 2020. PMID 32284030
• Chen C. Erythrocyte ENT1-AMPD3 Axis is an Essential Purinergic Hypoxia Sensor and Energy Regulator Combating CKD in a Mouse Model. J Am Soc Nephrol 2023. PMID 37725437
• Jaafar LS. 2,3-Diphosphoglycerate: the forgotten metabolic regulator of oxygen affinity. Br J Nutr 2025. PMID 41070558

22 references

• Woodson RD. Effect of increased blood oxygen affinity on work performance of rats. J Clin Invest 1973. PMID 4748508
• Makino N. Oxygen equilibria of hybrid-heme hemoglobins containing proto- and mesoheme groups. On the nonequivalence of alpha and beta chains. J Biol Chem 1978. PMID 24050
• Jaffé ER. Methemoglobin pathophysiology. Prog Clin Biol Res 1981. PMID 7022466
• Jaffé ER. Methaemoglobinaemia. Clin Haematol 1981. PMID 7011627
• Buerk DG. An evaluation of Easton's paradigm for the oxyhemoglobin equilibrium curve. Adv Exp Med Biol 1984. PMID 6534109
• Madsen H. Red cell 2,3-diphosphoglycerate and hemoglobin--oxygen affinity during normal pregnancy. Acta Obstet Gynecol Scand 1984. PMID 6496042
• Edelstone DI. Effects of maternal anemia on cardiac output, systemic oxygen consumption, and regional blood flow in pregnant sheep. Am J Obstet Gynecol 1987. PMID 3826225
• Wilkerson DK. Oxygen extraction ratio: a valid indicator of myocardial metabolism in anemia. J Surg Res 1987. PMID 3586630
• Wilkerson DK. Limits of cardiac compensation in anemic baboons. Surgery 1988. PMID 3375993
• King LG. Anemia of chronic renal failure in dogs. J Vet Intern Med 1992. PMID 1432900
• Mansouri A. Concise review: methemoglobinemia. Am J Hematol 1993. PMID 8416301
• Fox GA. Hematocrit modifies the circulatory control of systemic and myocardial oxygen utilization in septic sheep. Crit Care Med 1994. PMID 8124998
• Ostgaard G. [Perioperative and postoperative normovolemic anemia. Physiological compensation, monitoring and risk evaluation]. Tidsskr Nor Laegeforen 1996. PMID 8553339
• Papassotiriou I. Synthesized allosteric effectors of the hemoglobin molecule: a possible mechanism for improved erythrocyte oxygen release capability in hemoglobi. Exp Hematol 1998. PMID 9728926
• Metivier F. Pathophysiology of anaemia: focus on the heart and blood vessels. Nephrol Dial Transplant 2000. PMID 11032352
• Eckardt KU. Anaemia in end-stage renal disease: pathophysiological considerations. Nephrol Dial Transplant 2001. PMID 11590249
• Habler O. Hyperoxia in extreme hemodilution. Eur Surg Res 2002. PMID 11867921
• Villela NR. Microcirculatory effects of changing blood hemoglobin oxygen affinity during hemorrhagic shock resuscitation in an experimental model. Shock 2009. PMID 18948853
• Boĭko NV. [Biochemical characteristics of compensation of posthemorrhagic anemia in patients presenting with nasal bleeding]. Vestn Otorinolaringol 2010. PMID 21105337
• Saleh MC. NADH-dependent cytochrome b5 reductase and NADPH methemoglobin reductase activity in the erythrocytes of Oncorhynchus mykiss. Fish Physiol Biochem 2012. PMID 22733093
• Maeda S. Methemoglobin reduction by NADH-cytochrome b(5) reductase in Propsilocerus akamusi larvae. Comp Biochem Physiol B Biochem Mol Biol 2015. PMID 25829149
• Ericsson A. FT-4202, a selective pyruvate kinase R activator for sickle cell disease. Exp Hematol 2025. PMID 39549740

2 references

• Glogowska E. Mutations in the Gardos channel (KCNN4) are associated with hereditary xerocytosis. Blood 2015. PMID 26198474
• Vives-Corrons JL. Hereditary Spherocytosis: Linking Ion Transport Defects to Osmotic Gradient Ektacytometry Profiles-A Review. Int J Mol Sci 2026. PMID 41596371

25 references

• Cokelet GR. Dynamics of erythrocyte motion in filtration tests and in vivo flow. Scand J Clin Lab Invest Suppl 1981. PMID 6948404
• Weiss L. The red pulp of the spleen: structural basis of blood flow. Clin Haematol 1983. PMID 6352110
• Shatney CH. Complications of splenectomy. Acta Anaesthesiol Belg 1987. PMID 3327338
• Jakubovský J. [Functional morphology of the spleen]. Bratisl Lek Listy 1995. PMID 8624745
• Brew I. Post-splenectomy sepsis--the role of occupational health. Occup Med (Lond) 1996. PMID 8695777
• Chrobák L. [Splenomegaly (clinical importance, diagnosis and therapy)]. Vnitr Lek 2002. PMID 12061183
• Cohen AR. Thalassemia. Hematology Am Soc Hematol Educ Program 2004. PMID 15561674
• Kaplinsky C. Post-splenectomy antibiotic prophylaxis--unfinished story: to treat or not to treat?. Pediatr Blood Cancer 2006. PMID 16933244
• Soyer T. Portal vein thrombosis after splenectomy in pediatric hematologic disease: risk factors, clinical features, and outcome. J Pediatr Surg 2006. PMID 17101367
• Buesing KL. Partial splenectomy for hereditary spherocytosis: a multi-institutional review. J Pediatr Surg 2011. PMID 21238662
• Tuchscherer D. [What is the spleen needed for?]. Ther Umsch 2013. PMID 23454560
• Taniguchi LU. Overwhelming post-splenectomy infection: narrative review of the literature. Surg Infect (Larchmt) 2014. PMID 25318011
• Guizzetti L. Total versus partial splenectomy in pediatric hereditary spherocytosis: A systematic review and meta-analysis. Pediatr Blood Cancer 2016. PMID 27300151
• Rogulski R. Laparoscopic splenectomy for hereditary spherocytosis-preliminary report. Eur J Haematol 2016. PMID 26268883
• White NJ. Malaria parasite clearance. Malar J 2017. PMID 28231817
• Tahir F. Post-splenectomy Sepsis: A Review of the Literature. Cureus 2020. PMID 32195065
• Horvat M. Audit of Post-Splenectomy Prophylaxis in a Single Tertiary Center in Slovenia: Where Are We and What Should Be Done?. Surg Infect (Larchmt) 2021. PMID 32639189
• Celik SS. Clinical Characteristics and Treatment Outcome of Hereditary Spherocytosis: A Single Center's Experience. Sisli Etfal Hastan Tip Bul 2023. PMID 38268662
• Saldanha A. The immune thrombocytopenia paradox: Should we be concerned about thrombosis in ITP?. Thromb Res 2024. PMID 39137700
• Tang X. The efficacy of partial versus total splenectomy in the treatment of hereditary spherocytosis in children: a systematic review and meta-analysis. Pediatr Surg Int 2024. PMID 39470805
• Cappellini MD. Thalassemia and hypercoagulability. Hematology Am Soc Hematol Educ Program 2025. PMID 41348010
• Lluís N. Management of splanchnic venous thrombosis after splenectomy in hematologic diseases. systematic review, meta-analysis and consensus guidelines. Int J Surg 2025. PMID 41417989
• Saffioti NA. Escherichia coli α-hemolysin induces red blood cell retention in a microfluidic spleen-like device. Biophys J 2025. PMID 40077968
• Tefferi A. Essential Thrombocythemia: A Review. JAMA 2025. PMID 39869325
• Tessier B. Long-Term Outcome After Partial Splenectomy Compared to Total Splenectomy in Children With Spherocytosis. J Pediatr Surg 2025. PMID 40774475

37 references

• Anderson MJ. Human parvovirus infections. J Virol Methods 1987. PMID 2822752
• Rotbart HA. Human parvovirus infections. Annu Rev Med 1990. PMID 2158761
• Bender MA. Sickle Cell Disease. 1993. PMID 20301551
• Kalfa TA. EPB42-Related Hereditary Spherocytosis. 1993. PMID 24624460
• Brown KE. Parvovirus B19 infection and hematopoiesis. Blood Rev 1995. PMID 8563519
• Mittman N. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Am J Kidney Dis 1997. PMID 9398141
• Choi JW. Change in erythropoiesis with gestational age during pregnancy. Ann Hematol 2001. PMID 11233772
• Heegaard ED. Human parvovirus B19. Clin Microbiol Rev 2002. PMID 12097253
• Meyer O. Parvovirus B19 and autoimmune diseases. Joint Bone Spine 2003. PMID 12639611
• Koury MJ. New insights into erythropoiesis: the roles of folate, vitamin B12, and iron. Annu Rev Nutr 2004. PMID 15189115
• Eckardt KU. Regulation of erythropoietin production. Eur J Clin Invest 2005. PMID 16281953
• Johnson DW. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology (Carlton) 2007. PMID 17635745
• Tanno T. Growth differentiation factor 15 in erythroid health and disease. Curr Opin Hematol 2010. PMID 20182355
• Jelkmann W. Regulation of erythropoietin production. J Physiol 2011. PMID 21078592
• Wenger RH. Erythropoietin. Compr Physiol 2011. PMID 23733688
• Bunn HF. Erythropoietin. Cold Spring Harb Perspect Med 2013. PMID 23457296
• Haase VH. Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev 2013. PMID 23291219
• Orphanidou-Vlachou E. Extramedullary hemopoiesis. Semin Ultrasound CT MR 2014. PMID 24929265
• Nemtsas P. Neurological complications of beta-thalassemia. Ann Hematol 2015. PMID 25903043
• Piva E. Clinical utility of reticulocyte parameters. Clin Lab Med 2015. PMID 25676377
• Wongtong N. Monocytosis is associated with hemolysis in sickle cell disease. Hematology 2015. PMID 25875078
• Saliba AN. Morbidities in non-transfusion-dependent thalassemia. Ann N Y Acad Sci 2016. PMID 27186941
• Yoon S. Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon(®) and Eprex(®) following a single subcutaneous administ. Drug Des Devel Ther 2017. PMID 29138535
• Bolfa P. Thoracic and paraspinal extramedullary hematopoiesis in a cat with chronic non-regenerative anemia. JFMS Open Rep 2018. PMID 30245843
• Cherry-Bukowiec JR. Hepcidin and Anemia in Surgical Critical Care: A Prospective Cohort Study. Crit Care Med 2018. PMID 29517550
• El Nemer W. Ineffective erythropoiesis in sickle cell disease: new insights and future implications. Curr Opin Hematol 2021. PMID 33631786
• Hasegawa S. Evaluation of recombinant human erythropoietin responsiveness by measuring erythrocyte creatine content in haemodialysis patients. BMC Nephrol 2021. PMID 34895154
• Baird DC. Alpha- and Beta-thalassemia: Rapid Evidence Review. Am Fam Physician 2022. PMID 35289581
• Chaichompoo P. The Roles of Mitophagy and Autophagy in Ineffective Erythropoiesis in β-Thalassemia. Int J Mol Sci 2022. PMID 36142738
• Taylor CT. The effect of HIF on metabolism and immunity. Nat Rev Nephrol 2022. PMID 35726016
• Guzzo I. Anemia after kidney transplantation. Pediatr Nephrol 2023. PMID 36282330
• Liang R. Elevated CDKN1A (P21) mediates β-thalassemia erythroid apoptosis, but its loss does not improve β-thalassemic erythropoiesis. Blood Adv 2023. PMID 37672319
• Nahm CH. Lipocalin-2, Soluble Transferrin Receptor, and Erythropoietin in Anemia During Mild Renal Dysfunction. Int J Gen Med 2023. PMID 37637706
• Sato T. The roles of HIF-1α signaling in cardiovascular diseases. J Cardiol 2023. PMID 36127212
• Bloise S. Parvovirus B19 infection in children: a comprehensive review of clinical manifestations and management. Ital J Pediatr 2024. PMID 39696462
• Liu FF. Malaria and dyserythropoiesis: a mini review. Front Cell Infect Microbiol 2025. PMID 40980010
• Peng Z. KDM4B modulates autocrine IL6 in erythroblasts to prevent ineffective erythropoiesis. Leukemia 2025. PMID 40074853

32 references

• R'zik S. Serum soluble transferrin receptor concentration is an accurate estimate of the mass of tissue receptors. Exp Hematol 2001. PMID 11378262
• Schumacher YO. Effects of exercise on soluble transferrin receptor and other variables of the iron status. Br J Sports Med 2002. PMID 12055114
• Beguin Y. Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. Clin Chim Acta 2003. PMID 12589962
• Bérez V. Soluble transferrin receptor and mutations in hemochromatosis and transferrin genes in a general Catalan population. Clin Chim Acta 2005. PMID 15698609
• Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 2006. PMID 16627763
• Cappellini MD. Oral iron chelators. Annu Rev Med 2009. PMID 19630568
• Malyszko J. Hemojuvelin: the hepcidin story continues. Kidney Blood Press Res 2009. PMID 19287179
• McLeod C. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering wi. Health Technol Assess 2009. PMID 19068191
• Finberg KE. Down-regulation of Bmp/Smad signaling by Tmprss6 is required for maintenance of systemic iron homeostasis. Blood 2010. PMID 20200349
• Lee DH. Neogenin inhibits HJV secretion and regulates BMP-induced hepcidin expression and iron homeostasis. Blood 2010. PMID 20065295
• Lulla RR. Elevated soluble transferrin receptor levels reflect increased erythropoietic drive rather than iron deficiency in pediatric sickle cell disease. Pediatr Blood Cancer 2010. PMID 20486179
• Meerpohl JJ. Deferasirox for managing transfusional iron overload in people with sickle cell disease. Cochrane Database Syst Rev 2010. PMID 20687088
• Musallam KM. Iron chelation therapy for transfusional iron overload: a swift evolution. Hemoglobin 2011. PMID 21910602
• Fuqua BK. Intestinal iron absorption. J Trace Elem Med Biol 2012. PMID 22575541
• Patel M. Non transferrin bound iron: nature, manifestations and analytical approaches for estimation. Indian J Clin Biochem 2012. PMID 24082455
• Gkouvatsos K. Iron-dependent regulation of hepcidin in Hjv-/- mice: evidence that hemojuvelin is dispensable for sensing body iron levels. PLoS One 2014. PMID 24409331
• Lesjak M. Quercetin inhibits intestinal iron absorption and ferroportin transporter expression in vivo and in vitro. PLoS One 2014. PMID 25058155
• Marsella M. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease. Hematol Oncol Clin North Am 2014. PMID 25064709
• Przybyszewska J. The role of hepcidin, ferroportin, HCP1, and DMT1 protein in iron absorption in the human digestive tract. Prz Gastroenterol 2014. PMID 25276251
• Kent P. Hfe and Hjv exhibit overlapping functions for iron signaling to hepcidin. J Mol Med (Berl) 2015. PMID 25609138
• Frazer DM. Ferroportin Is Essential for Iron Absorption During Suckling, But Is Hyporesponsive to the Regulatory Hormone Hepcidin. Cell Mol Gastroenterol Hepatol 2017. PMID 28462381
• Sato M. Increased Duodenal Iron Absorption through Upregulation of Ferroportin 1 due to the Decrement in Serum Hepcidin in Patients with Chronic Hepatiti. Can J Gastroenterol Hepatol 2018. PMID 30186818
• Knutson MD. Non-transferrin-bound iron transporters. Free Radic Biol Med 2019. PMID 30316781
• Silvestri L. Hepcidin and the BMP-SMAD pathway: An unexpected liaison. Vitam Horm 2019. PMID 30798817
• Xiao X. Bone morphogenic proteins in iron homeostasis. Bone 2020. PMID 32585319
• Sugiura T. Analytical evaluation of serum non-transferrin-bound iron and its relationships with oxidative stress and cardiac load in the general population. Medicine (Baltimore) 2021. PMID 33607814
• Silva AMN. The (Bio)Chemistry of Non-Transferrin-Bound Iron. Molecules 2022. PMID 35335148
• —. . 2023. PMID 38502749
• Bruzzese A. Iron chelation therapy. Eur J Haematol 2023. PMID 36708354
• Girelli D. Diagnosis and management of hereditary hemochromatosis: lifestyle modification, phlebotomy, and blood donation. Hematology Am Soc Hematol Educ Program 2024. PMID 39644049
• Duca L. The Relationship Between Non-Transferrin-Bound Iron (NTBI), Labile Plasma Iron (LPI), and Iron Toxicity. Int J Mol Sci 2025. PMID 40650208
• Enko D. Physiology of Iron Metabolism. Clin Lab 2025. PMID 40066539

31 references

• Lundh B. Heme catabolism, carbon monoxide production and red cell survival in anemia. Acta Med Scand 1975. PMID 1124665
• Soloway RD. Pigment gallstones. Gastroenterology 1977. PMID 318581
• Werner B. Endogenous carbon monoxide production after bicycle exercise in healthy subjects and in patients with hereditary spherocytosis. Scand J Clin Lab Invest 1980. PMID 7414250
• Rothuizen J. Bilirubin metabolism in canine hepatobiliary and haemolytic disease. Vet Q 1987. PMID 3672859
• Trotman BW. Pigment gallstone disease. Gastroenterol Clin North Am 1991. PMID 2022417
• Iyer L. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A. Clin Pharmacol Ther 1999. PMID 10340924
• Maruo Y. [UDP-glucuronosyltransferase]. Nihon Eiseigaku Zasshi 2002. PMID 11868392
• American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004. PMID 15231951
• Amin SB. Clinical assessment of bilirubin-induced neurotoxicity in premature infants. Semin Perinatol 2004. PMID 15686265
• Frank JE. Diagnosis and management of G6PD deficiency. Am Fam Physician 2005. PMID 16225031
• Chang JL. UGT1A1 polymorphism is associated with serum bilirubin concentrations in a randomized, controlled, fruit and vegetable feeding trial. J Nutr 2007. PMID 17374650
• Watson RL. Hyperbilirubinemia. Crit Care Nurs Clin North Am 2009. PMID 19237047
• Cariati A. Limits and perspective of oral therapy with statins and aspirin for the prevention of symptomatic cholesterol gallstone disease. Expert Opin Pharmacother 2012. PMID 22607008
• Gil J. Gilbert syndrome: the UGT1A1*28 promoter polymorphism as a biomarker of multifactorial diseases and drug metabolism. Biomark Med 2012. PMID 22448797
• Stinton LM. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut Liver 2012. PMID 22570746
• Bhutani VK. Bilirubin neurotoxicity in preterm infants: risk and prevention. J Clin Neonatol 2013. PMID 24049745
• Cariati A. Blackberry pigment (whitlockite) gallstones in uremic patient. Clin Res Hepatol Gastroenterol 2013. PMID 22959097
• Hulzebos CV. Bilirubin-albumin binding, bilirubin/albumin ratios, and free bilirubin levels: where do we stand?. Semin Perinatol 2014. PMID 25304058
• Morioka I. Disorders of bilirubin binding to albumin and bilirubin-induced neurologic dysfunction. Semin Fetal Neonatal Med 2015. PMID 25432488
• Ahlfors CE. The Bilirubin Binding Panel: A Henderson-Hasselbalch Approach to Neonatal Hyperbilirubinemia. Pediatrics 2016. PMID 27609825
• Amin SB. Bilirubin Binding Capacity in the Preterm Neonate. Clin Perinatol 2016. PMID 27235205
• Mitra S. Neonatal jaundice: aetiology, diagnosis and treatment. Br J Hosp Med (Lond) 2017. PMID 29240507
• Kaplan M. Hemolysis and Glucose-6-Phosphate Dehydrogenase Deficiency-Related Neonatal Hyperbilirubinemia. Neonatology 2018. PMID 29940590
• Chávez-Peña T. Prevalence of UGT1A1 (TA)n promoter polymorphism in Panamanians neonates with G6PD deficiency. J Genet 2020. PMID 33622990
• Stevenson DK. Increased Carbon Monoxide Washout Rates in Newborn Infants. Neonatology 2020. PMID 31634890
• Par EJ. Neonatal Hyperbilirubinemia: Evaluation and Treatment. Am Fam Physician 2023. PMID 37192079
• Chastain AP. Managing neonatal hyperbilirubinemia: An updated guideline. JAAPA 2024. PMID 39259272
• Mobaraki S. Cabozantinib Induces Isolated Hyperbilirubinemia in Renal Cell Carcinoma Patients carrying the UGT1A1*28 Polymorphism. Clin Genitourin Cancer 2024. PMID 39155162
• Jagroo J. Confronting Cholelithiasis: A Case Series of Patients With Sickle Cell Disease and Gallstones. Cureus 2025. PMID 40225473
• Wickremasinghe AC. Neonatal Hyperbilirubinemia. Pediatr Clin North Am 2025. PMID 40619190
• Yang G. End-tidal carbon monoxide levels as a point-of-care biomarker for the early detection of hemolytic disease in Chinese neonates. Clin Chim Acta 2025. PMID 40383361

13 references

• Vanderschueren D. Skeletal effects of estrogen deficiency as induced by an aromatase inhibitor in an aged male rat model. Bone 2000. PMID 11062346
• Nathan L. Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase. Proc Natl Acad Sci U S A 2001. PMID 11248122
• Kanakis GA. EAA clinical practice guidelines-gynecomastia evaluation and management. Andrology 2019. PMID 31099174
• Yang C. Clinical application of aromatase inhibitors to treat male infertility. Hum Reprod Update 2021. PMID 34871401
• Guo B. Efficacy and safety of letrozole or anastrozole in the treatment of male infertility with low testosterone-estradiol ratio: A meta-analysis and s. Andrology 2022. PMID 35438843
• Idris IM. Epidemiology and treatment of priapism in sickle cell disease. Hematology Am Soc Hematol Educ Program 2022. PMID 36485155
• van Dijk MJ. One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study. Blood Adv 2023. PMID 37934880
• van Beers EJ. Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiency. Blood Adv 2024. PMID 38330179
• Algeri M. The ENERGIZE trial: Is mitapivat ready to take center stage in NTDT management?. Med 2025. PMID 40945502
• Conrey A. Long-term mitapivat treatment is safe and efficacious in patients with sickle cell disease. Blood Red Cells Iron 2025. PMID 41809202
• Idowu M. Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placeb. Lancet Haematol 2025. PMID 39644907
• Kuo KHM. Long-term efficacy and safety of mitapivat in non-transfusion-dependent α- or β-thalassaemia: An open-label phase 2 study. Br J Haematol 2025. PMID 40394935
• Taher AT. Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blin. Lancet 2025. PMID 40544857

8 references

• Trobridge GD. Stem cell selection in vivo using foamy vectors cures canine pyruvate kinase deficiency. PLoS One 2012. PMID 23028826
• van Straaten S. Worldwide study of hematopoietic allogeneic stem cell transplantation in pyruvate kinase deficiency. Haematologica 2018. PMID 29242305
• Quintana-Bustamante O. Gene editing of PKLR gene in human hematopoietic progenitors through 5' and 3' UTR modified TALEN mRNA. PLoS One 2019. PMID 31618280
• Fañanas-Baquero S. Clinically relevant gene editing in hematopoietic stem cells for the treatment of pyruvate kinase deficiency. Mol Ther Methods Clin Dev 2021. PMID 34485608
• Ma ZY. Allogeneic hematopoietic stem cell transplantation in a 3-year-old boy with congenital pyruvate kinase deficiency: A case report. World J Clin Cases 2021. PMID 33969077
• Morado M. Consensus document for the diagnosis and treatment of pyruvate kinase deficiency. Med Clin (Barc) 2021. PMID 33431182
• Fañanas-Baquero S. Specific correction of pyruvate kinase deficiency-causing point mutations by CRISPR/Cas9 and single-stranded oligodeoxynucleotides. Front Genome Ed 2023. PMID 37188156
• Pang Y. Case report: Modified transplantation for pediatric patients with pyruvate kinase deficiency. Front Immunol 2024. PMID 39635530

27 references

• Ghidini A. Hepatosplenomegaly as the only prenatal finding in a fetus with pyruvate kinase deficiency anemia. Am J Perinatol 1991. PMID 1987968
• Filosa A. Longitudinal monitoring of bone mineral density in thalassemic patients. Genetic structure and osteoporosis. Acta Paediatr 1997. PMID 9174216
• Ghidini A. Severe pyruvate kinase deficiency anemia. A case report. J Reprod Med 1998. PMID 9749428
• Almeida A. Bone involvement in sickle cell disease. Br J Haematol 2005. PMID 15877730
• Lin EE. Hemolytic anemia-associated pulmonary hypertension in sickle cell disease. Curr Hematol Rep 2005. PMID 15720960
• Kato GJ. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death. Blood 2006. PMID 16291595
• Machado RF. Sickle cell anemia-associated pulmonary arterial hypertension. J Bras Pneumol 2007. PMID 18026658
• Vermylen C. What is new in iron overload?. Eur J Pediatr 2008. PMID 17899187
• Newaskar M. Asthma in sickle cell disease. ScientificWorldJournal 2011. PMID 21623460
• Mohamed S. A case of severe pyruvate kinase deficiency in a primigravida: successful outcome. Obstet Med 2013. PMID 27757165
• Adams-Graves P. Bone mineral density patterns in vitamin D deficient African American men with sickle cell disease. Am J Med Sci 2014. PMID 23538935
• Irwig MS. Bone health in hypogonadal men. Curr Opin Urol 2014. PMID 25144148
• Barcellini W. Clinical Applications of Hemolytic Markers in the Differential Diagnosis and Management of Hemolytic Anemia. Dis Markers 2015. PMID 26819490
• Potoka KP. Vasculopathy and pulmonary hypertension in sickle cell disease. Am J Physiol Lung Cell Mol Physiol 2015. PMID 25398989
• Gordeuk VR. Pathophysiology and treatment of pulmonary hypertension in sickle cell disease. Blood 2016. PMID 26758918
• Lal A. Assessment and treatment of pain in thalassemia. Ann N Y Acad Sci 2016. PMID 27124110
• Kato GJ. Intravascular hemolysis and the pathophysiology of sickle cell disease. J Clin Invest 2017. PMID 28248201
• Abid S. New Nitric Oxide Donor NCX 1443: Therapeutic Effects on Pulmonary Hypertension in the SAD Mouse Model of Sickle Cell Disease. J Cardiovasc Pharmacol 2018. PMID 29438213
• Bernardi MH. Hemoadsorption does not Have Influence on Hemolysis During Cardiopulmonary Bypass. ASAIO J 2019. PMID 30325849
• Niccoli Asabella A. Sickle cell diseases: What can nuclear medicine offer?. Hell J Nucl Med 2019. PMID 30843001
• Etemad K. Quality of Life and Related Factors in β-Thalassemia Patients. Hemoglobin 2021. PMID 34409903
• Jang JH. Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study. Blood Adv 2022. PMID 35561315
• Al-Samkari H. Mitapivat for Acquired Pyruvate Kinase Deficiency. Pediatr Blood Cancer 2025. PMID 39538432
• Jain P. Spectrum of Ophthalmic Manifestations in Patients With Transfusion-Dependent Thalassemia. Cureus 2025. PMID 40370899
• Kariki O. Biochemical evidence and clinical significance of hemolysis following catheter ablation with a lattice-tip PFA catheter. J Interv Card Electrophysiol 2025. PMID 41129021
• Koh TWY. Intravascular haemolysis following pulsed field ablation pulmonary vein isolation for atrial fibrillation: a systematic review. Open Heart 2025. PMID 41213824
• Ahmed K. Adult survivors of sickle cell disease, transfusion-dependent beta-thalassaemia and childhood acute leukaemia in England: protocol for a mixed me. BMJ Open 2026. PMID 41628927

18 references

• Siems WG. Erythrocyte free radical and energy metabolism. Clin Nephrol 2000. PMID 10746800
• Cappellini MD. Glucose-6-phosphate dehydrogenase deficiency. Lancet 2008. PMID 18177777
• Hess JR. Red cell storage. J Proteomics 2010. PMID 19914410
• van Zwieten R. Inborn defects in the antioxidant systems of human red blood cells. Free Radic Biol Med 2014. PMID 24316370
• D'Alessandro A. Red blood cell storage in additive solution-7 preserves energy and redox metabolism: a metabolomics approach. Transfusion 2015. PMID 26271632
• Al-Abdi SY. Decreased Glutathione S-transferase Level and Neonatal Hyperbilirubinemia Associated with Glucose-6-phosphate Dehydrogenase Deficiency: A Perspec. Am J Perinatol 2017. PMID 27464020
• Belfield KD. Review and drug therapy implications of glucose-6-phosphate dehydrogenase deficiency. Am J Health Syst Pharm 2018. PMID 29305344
• Gehrke S. Metabolomics evaluation of early-storage red blood cell rejuvenation at 4°C and 37°C. Transfusion 2018. PMID 29687892
• Ghashghaeinia M. Proliferating tumor cells mimick glucose metabolism of mature human erythrocytes. Cell Cycle 2019. PMID 31154896
• La Vieille S. Dietary restrictions for people with glucose-6-phosphate dehydrogenase deficiency. Nutr Rev 2019. PMID 30380124
• Li R. Exploring the role of glucose‑6‑phosphate dehydrogenase in cancer (Review). Oncol Rep 2020. PMID 33125150
• Luzzatto L. Glucose-6-phosphate dehydrogenase deficiency. Blood 2020. PMID 32702756
• Lee HY. Glucose-6-Phosphate Dehydrogenase Deficiency and Neonatal Hyperbilirubinemia: Insights on Pathophysiology, Diagnosis, and Gene Variants in Diseas. Front Pediatr 2022. PMID 35685917
• D'Alessandro A. Red Blood Cell Storage: From Genome to Exposome Towards Personalized Transfusion Medicine. Transfus Med Rev 2023. PMID 37574398
• D'Alessandro A. Red Blood Cell Metabolism In Vivo and In Vitro. Metabolites 2023. PMID 37512500
• Nemkov T. Supercooled storage of red blood cells slows down the metabolic storage lesion. Sci Rep 2025. PMID 41044137
• Wang X. Obesity-aggravated erythrocyte injury in ischaemia-reperfusion: Interlinked oxidative stress, metabolic reprogramming, and cytoskeletal destabili. Life Sci 2025. PMID 40975374
• Mak GK. Glucose-6-Phosphate Dehydrogenase Deficiency. 2026. PMID 29262208

13 references

• Betts A. A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing. AAPS J 2019. PMID 31119428
• El-Khateeb E. Quantitative mass spectrometry-based proteomics in the era of model-informed drug development: Applications in translational pharmacology and rec. Pharmacol Ther 2019. PMID 31376433
• Elmokadem A. Quantitative Systems Pharmacology and Physiologically-Based Pharmacokinetic Modeling With mrgsolve: A Hands-On Tutorial. CPT Pharmacometrics Syst Pharmacol 2019. PMID 31652028
• Nguyen LM. A quantitative systems pharmacology model of hyporesponsiveness to erythropoietin in rats. J Pharmacokinet Pharmacodyn 2021. PMID 34100188
• Ball K. Strategies for clinical dose optimization of T cell-engaging therapies in oncology. MAbs 2023. PMID 36823042
• Ji Y. Quantitative systems pharmacology model of GITR-mediated T cell dynamics in tumor microenvironment. CPT Pharmacometrics Syst Pharmacol 2023. PMID 36710369
• Li X. Combining network pharmacology, molecular docking, molecular dynamics simulation, and experimental verification to examine the efficacy and immun. Front Immunol 2023. PMID 37575231
• Arsène S. In Silico Clinical Trials: Is It Possible?. Methods Mol Biol 2024. PMID 37702936
• GBD 2021 US Burden of Disease and Forecasting Collaborators. Burden of disease scenarios by state in the USA, 2022-50: a forecasting analysis for the Global Burden of Disease Study 2021. Lancet 2024. PMID 39645377
• Luo Y. Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors. Cell 2024. PMID 38971151
• GBD 2023 Disease and Injury and Risk Factor Collaborators. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, i. Lancet 2025. PMID 41092926
• GBD 2023 Lower Respiratory Infections and Antimicrobial Resistance Collaborators. Global burden of lower respiratory infections and aetiologies, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet Infect Dis 2026. PMID 41412141
• GBD 2023 Meningitis & Antimicrobial Resistance Collaborators. Global, regional, and national burden of meningitis, its risk factors, and aetiologies, 1990-2023: a systematic analysis for the Global Burden of. Lancet Neurol 2026. PMID 41911930